Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney, Polycystic Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

NCT02160145
View directory record Official record
Conditions
Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan (OPC-41061), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Study of Metformin Therapy in ADPKD

NCT02903511
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

NCT02656017
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Kyongtae Ty Bae, M.D., Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT03096080
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Recessive
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 12, 2026, 4:40 PM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD

NCT05193981
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 12, 2026, 4:40 PM EDT
Completed No phase listed Observational

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

NCT04407481
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease

NCT02225860
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Diet and water adjustment
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 12, 2026, 4:40 PM EDT
Terminated Phase 3 Interventional Results available

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

NCT05208866
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult
Interventions
Lixivaptan
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05521191
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
Interventions
RGLS8429, Placebo
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Mesa, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 12, 2026, 4:40 PM EDT
Terminated Not applicable Interventional Results available

Polycystic Liver Disease in Kidney Transplant

NCT00934791
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
Tacrolimus, Sirolimus, Mycophenolate Mofetil, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 12, 2026, 4:40 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

NCT04064346
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease

NCT03342742
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Weight Loss
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 12, 2026, 4:40 PM EDT
Recruiting No phase listed Observational

A Prospective Observational Study of Foam Sclerotherapy .

NCT04111692
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, Renal Cyst, Autosomal Dominant Polycystic Liver Disease, Hepatic Cyst
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 12, 2026, 4:40 PM EDT
Recruiting Phase 3 Interventional

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT04782258
View directory record Official record
Conditions
Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions
Tolvaptan Suspension, Tolvaptan Tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
28 Days to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06345755
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo, Midazolam
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 12, 2026, 4:40 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

NCT03523728
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

NCT02558595
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Niacinamide, Placebo
Dietary Supplement · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Octreotide in Severe Polycystic Liver Disease

NCT00426153
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Bosutinib For Autosomal Dominant Polycystic Kidney Disease

NCT01233869
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Bosutinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
20
States / cities
Phoenix, Arizona • Tempe, Arizona • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00413777
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 12, 2026, 4:40 PM EDT
Completed No phase listed Observational

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT01430494
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Not listed
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
12 Years to 70 Years
Enrollment
3,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
102
States / cities
Peoria, Arizona • Tempe, Arizona • Azusa, California + 89 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

NCT03203642
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Tesevatinib, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
La Jolla, California • La Mesa, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 12, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease

NCT04534985
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Dietary
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 12, 2026, 4:40 PM EDT